查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1692299

子宮頸癌診斷市場 - 全球產業規模、佔有率、趨勢、機會和預測，按檢測類型、最終用戶、地區和競爭細分，2020-2030 年預測

Cervical Cancer Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球子宮頸癌診斷市場價值為 82.7 億美元，預計到 2030 年將達到 118.9 億美元，預測期內複合年成長率為 6.24%。由於對篩檢和診斷測試的需求增加，中年女性子宮頸癌發生率的上升預計將在未來幾年推動市場成長。根據世界衛生組織的出版物，子宮頸癌是全球女性中第四大常見癌症。此外，根據美國癌症協會2023年的資料，美國預計將診斷出約13,960例侵襲性子宮頸癌，導致約4,310名女性死亡。

市場概況
預測期 2026-2030
2024 年市場規模 82.7 億美元
2030 年市場規模 118.9 億美元
2025-2030 年複合年成長率 6.24%
成長最快的領域 巴氏試驗
最大的市場 北美洲

主要市場促進因素

提高認知和教育

主要市場挑戰

醫療不平等

主要市場趨勢

分子診斷革命

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球子宮頸癌診斷市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依檢查類型（巴氏抹片檢查、HPV 檢測、陰道鏡檢查、子宮頸切片、膀胱鏡檢查）
    • 按最終使用者（醫院和診所、診斷實驗室、其他）
    • 按地區
    • 按公司分類（2024）
  • 產品市場圖
    • 按測試類型
    • 按最終用途
    • 按地區

第 6 章：北美子宮頸癌診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲子宮頸癌診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 法國
    • 義大利
    • 西班牙

第 8 章：亞太地區子宮頸癌診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 日本
    • 印度
    • 澳洲
    • 韓國

第 9 章：南美洲子宮頸癌診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲子宮頸癌診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 合併與收購
  • 產品發布

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Becton Dickinson and Company
  • Hologic Inc
  • CooperSurgical Inc
  • Siemens Healthineers AG
  • Quigan NV
  • F. Hoffmann-La Roche Ltd
  • Oncgnostics GmbH
  • Quest Diagnostics

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 20916

Global Cervical Cancer Diagnostic Market was valued at USD 8.27 billion in 2024 and is expected to reach USD 11.89 billion by 2030 with a CAGR of 6.24% during the forecast period. The rise in cervical cancer rates among women in the middle age bracket is anticipated to drive market growth in the coming years due to the increased demand for screening and diagnostic tests. According to the World Health Organization's publications, cervical cancer is ranked as the fourth most prevalent cancer among women worldwide. Additionally, according to data from the American Cancer Society in 2023, it is estimated that approximately 13,960 cases of invasive cervical cancer will be diagnosed, resulting in approximately 4,310 female fatalities in the United States.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 8.27 Billion
Market Size 2030USD 11.89 Billion
CAGR 2025-20306.24%
Fastest Growing SegmentPap testing
Largest MarketNorth America

Key Market Drivers

Rising Awareness and Education

Cervical cancer is a formidable global health challenge, but increasing awareness and education are proving to be powerful catalysts for growth in the Global Cervical Cancer Diagnostic Market. The recognition of the importance of early detection and regular screenings is essential for reducing the burden of this disease. Awareness campaigns, educational programs, and advocacy efforts have been instrumental in empowering women with knowledge about cervical cancer and its prevention. These initiatives disseminate information about the disease, its risk factors, and the significance of regular screenings. As women become more informed, they are more likely to take proactive steps toward their health, including undergoing cervical cancer diagnostics.

Awareness and education campaigns stress the importance of early detection. Women who understand the benefits of regular screenings are more likely to schedule appointments with healthcare providers. This increased demand for screening services directly contributes to the growth of the cervical cancer diagnostic market. Cervical cancer screenings, such as Pap smears, can be intimidating for many women due to fear or discomfort. However, informed women are more likely to overcome these fears, knowing that early detection can be life-saving. Reducing the stigma and fear associated with cervical cancer diagnostics encourages more women to seek these services, further boosting market growth.

Key Market Challenges

Healthcare Inequity

Healthcare disparities exist in many parts of the world, and cervical cancer diagnostic services are not exempt from these inequalities. Women in marginalized communities often face barriers such as limited financial resources, lack of transportation, and inadequate healthcare infrastructure, which restrict their access to screening services.

Key Market Trends

Molecular Diagnostics Revolution

Molecular diagnostic techniques, including nucleic acid testing, have gained prominence in cervical cancer diagnosis. These methods offer increased sensitivity and specificity in detecting human papillomavirus (HPV) infections and identifying specific viral strains associated with cervical cancer. The trend is moving towards molecular testing becoming a standard procedure in cervical cancer screening, enabling more precise diagnoses.

Key Market Players

  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Becton Dickinson and Company
  • Hologic Inc
  • CooperSurgical Inc
  • Siemens Healthineers AG
  • Quigan NV
  • F. Hoffmann-La Roche Ltd
  • Oncgnostics GmbH
  • Quest Diagnostics

Report Scope:

In this report, the Global Cervical Cancer Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cervical Cancer Diagnostic Market, By Test Type:

  • Pap testing
  • HPV testing
  • Colposcopy
  • Cervical biopsies
  • Cystoscopy

Cervical Cancer Diagnostic Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Cervical Cancer Diagnostic Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cervical Cancer Diagnostic Market.

Available Customizations:

Global Cervical Cancer Diagnostic market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cervical Cancer Diagnostic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 5.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Test Type
    • 5.3.2. By End Use
    • 5.3.3. By Region

6. North America Cervical Cancer Diagnostic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 6.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cervical Cancer Diagnostic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Cervical Cancer Diagnostic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Cervical Cancer Diagnostic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By End Use

7. Europe Cervical Cancer Diagnostic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 7.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cervical Cancer Diagnostic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By End Use
    • 7.3.2. United Kingdom Cervical Cancer Diagnostic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By End Use
    • 7.3.3. France Cervical Cancer Diagnostic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Cervical Cancer Diagnostic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Cervical Cancer Diagnostic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By End Use

8. Asia-Pacific Cervical Cancer Diagnostic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 8.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cervical Cancer Diagnostic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By End Use
    • 8.3.2. Japan Cervical Cancer Diagnostic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By End Use
    • 8.3.3. India Cervical Cancer Diagnostic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By End Use
    • 8.3.4. Australia Cervical Cancer Diagnostic Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By End Use
    • 8.3.5. South Korea Cervical Cancer Diagnostic Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By End Use

9. South America Cervical Cancer Diagnostic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 9.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cervical Cancer Diagnostic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Cervical Cancer Diagnostic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Cervical Cancer Diagnostic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Cervical Cancer Diagnostic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 10.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cervical Cancer Diagnostic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Cervical Cancer Diagnostic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Cervical Cancer Diagnostic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By End Use
    • 10.3.4. Kuwait Cervical Cancer Diagnostic Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Test Type
        • 10.3.4.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.2. Product Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Thermo Fisher Scientific Inc
  • 14.3. Becton Dickinson and Company
  • 14.4. Hologic Inc
  • 14.5. CooperSurgical Inc
  • 14.6. Siemens Healthineers AG
  • 14.7. Quigan NV
  • 14.8. F. Hoffmann-La Roche Ltd
  • 14.9. Oncgnostics GmbH
  • 14.10. Quest Diagnostics

15. Strategic Recommendations

16. About Us & Disclaimer